Superior 3-year (13.8%) and 5-year (10.5%) annualized returns compared to XLV, with higher dividend yield (2.0%). Recommended as the better buy for recent performance, though concentrated portfolio carries higher risk and expense ratio (0.36%).
Offers higher 5-year returns (28.7% vs 25.7%) and higher dividend yield (2% vs 1.6%), but criticized for high concentration risk (26 holdings with top 5 at 50% of portfolio), higher expense ratio (0.36%), and deeper maximum drawdown (-20.3%). Suitable only for aggressive investors willing to accept elevated risk.
Lower expense ratio (0.36%), higher dividend yield (2.00%), larger AUM ($879.5M) providing better liquidity, and superior 5-year growth ($1,632 vs $1,530), making it attractive for income-oriented and long-term investors.
Articles that tag PPH but are mainly about other companies.
U.S. pharma sector has survived previous pricing threats; latest agreements primarily target Medicaid and foreign companies, limiting direct impact on broader U.S. pharma market.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology